Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023
06 Novembre 2023 - 10:30PM
Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it
will be showcasing its latest product innovations at the Society
for Neuroscience (SfN) conference from November 12-15, 2023, in
Washington, D.C. Complementing an already extensive product line,
the new innovations provide exciting new opportunities for
advancing preclinical and organoid-focused research and therapy
development by a broad range of customers.
The latest advancements from the Company’s Data
Sciences International (DSI) preclinical business expand the reach
of DSI’s industry-leading, GLP-compliant Ponemah™ preclinical data
management platform. These advancements include DSI’s new SoHo™
implantable telemetry solution for small animal models and its
VivaMARS™ high-capacity behavior monitoring system.
Integrated with the Ponemah platform, the SoHo
implantable real-time telemetry solution enables researchers to
collect, manage, analyze and report findings from multiple
concurrent small animal models in a more natural shared housing
environment. In addition, the SoHo solution allows data to be
collected over longer time periods and opens exciting new
opportunities for longitudinal studies. The SoHo solution is
designed to support the customer’s business needs by reducing
operating costs and test cycle times, enabling increased testing
throughput.
The VivaMARS system combines the Company’s
real-time high precision Panlab® activity monitoring technology
with its Ponemah preclinical data management platform to create an
integrated GLP-compliant solution. The system is ideally suited to
meet the high throughput, automated neuropharmacology and
neurotoxicology testing needs of CROs and pharma companies, in
addition to longitudinal behavior studies carried out by leading
research and academic institutes. For more information on the
VivaMARS system, please visit the DSI website at
https://www.datasci.com/products/behavior/vivamars-mobile-activity-rack-system.
From our Multi Channel Systems team, the Company
will exhibit its first organoid-centric mesh Microelectrode Array
(MEA). Expanding its recognized leadership position in in-vitro MEA
products, the new mesh MEA system allows researchers to capture
precise electrophysiology measurements from inside the organoid in
real time. This new mesh MEA technology is designed for the
emerging applications of organoids in research and discovery,
safety pharmacology and toxicology. The Company will present early
research results using this novel technology in neuroscience
studies. For more information on our mesh MEA products and organoid
research, please visit our website at
https://www.harvardbioscience.com/applications/organoid-research.
Jim Green, Harvard Bioscience Chairman and CEO
said, “These new product innovations reaffirm our commitment to
driving fundamental advances in academic research and discovery
while expanding our product lines to meet the needs of our
industrial customers in CRO, pharma and biotech.”
Serge Savard, Harvard Bioscience Vice President
of Product Management said, “With the integration of these new
applications in a single data management platform, our Ponemah
system provides neuroscience researchers with a powerful way of
exploring combination studies of behavior, telemetry, and other
modalities. And with the introduction of our organoid-centric mesh
MEA, researchers can characterize and manipulate firing patterns
from neuronal, cardiac and numerous other organ proxies.”
Booth at Society for Neuroscience
Conference 2023
The Company will be exhibiting a range of
solutions at Neuroscience 2023 at booth #1509, at the Walter E.
Washington Convention Center (801 Mt Vernon Place NW 801 Allen Y.
Lew Place NW, Washington, D.C.). Representatives will be present
during exhibit hours from Sunday November 12, 2023 through
Wednesday November 15, 2023 from 9.30 a.m. to 5.00 p.m. EST.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer,
manufacturer and seller of technologies, products and services that
enable fundamental advances in life science applications, including
research, pharmaceutical and therapy discovery, bio-production and
preclinical testing for pharmaceutical and therapy development. Our
customers range from renowned academic institutions and government
laboratories to the world’s leading pharmaceutical, biotechnology
and contract research organizations. With operations in North
America, Europe, and China, we sell through a combination of direct
and distribution channels to customers around the world.
For more information, please visit our website
at https://www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking
statements within the meaning of the federal securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions or statements that do not relate
to historical matters. Forward-looking statements include, but are
not limited to, information concerning expected future financial
and operational performance including revenues, gross margins,
earnings, cash and debt position, growth and the introduction of
new products, and the strength of the Harvard Bioscience, Inc. (the
“Company”) market position and business model. Forward-looking
statements are not guarantees of future performance and involve
known and unknown uncertainties, risks, assumptions, and
contingencies, many of which are outside the Company’s control.
Risks and other factors that could cause the Company’s actual
results to differ materially from those described its
forward-looking statements include those described in the “Risk
Factors” section of the Company’s most recently filed Annual Report
on Form 10-K as well as in the Company’s other filings with the
Securities and Exchange Commission. Forward-looking statements are
based on the Company’s expectations and assumptions as of the date
of this document. Except as required by law, the Company assumes no
obligation to update forward-looking statements to reflect any
change in expectations, even as new information becomes
available.
Inquiries:
CustomersSales@datasci.com
Investors and MediaHarvard Bioscience,
Inc.Investor Relationsinvestors@harvardbioscience.com(508)
893-3120
Harvard Bioscience (NASDAQ:HBIO)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Harvard Bioscience (NASDAQ:HBIO)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024